HC Wainwright Forecasts Weaker Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at HC Wainwright lowered their Q4 2025 earnings per share estimates for shares of Legend Biotech in a research report issued on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn $0.11 per share for the quarter, down from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

Other research analysts have also issued research reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. Guggenheim reaffirmed a “neutral” rating on shares of Legend Biotech in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $78.00 price target on shares of Legend Biotech in a research report on Monday, December 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.09.

Legend Biotech Trading Down 2.2 %

LEGN opened at $37.20 on Friday. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of -39.16 and a beta of 0.19. Legend Biotech has a 52 week low of $30.17 and a 52 week high of $65.45. The business’s 50 day moving average is $35.68 and its two-hundred day moving average is $40.85. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27.

Legend Biotech (NASDAQ:LEGN) last posted its earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.46. The firm had revenue of $186.50 million during the quarter, compared to analysts’ expectations of $179.00 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm’s revenue was up 134.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.40) earnings per share.

Institutional Trading of Legend Biotech

Institutional investors have recently bought and sold shares of the company. Signaturefd LLC boosted its position in Legend Biotech by 1,052.7% during the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock worth $56,000 after purchasing an additional 1,579 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Legend Biotech in the fourth quarter valued at $56,000. Shell Asset Management Co. lifted its position in shares of Legend Biotech by 62.0% in the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company’s stock valued at $68,000 after acquiring an additional 800 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Legend Biotech in the fourth quarter valued at $77,000. Finally, Quadrant Capital Group LLC lifted its position in shares of Legend Biotech by 4,296.6% in the fourth quarter. Quadrant Capital Group LLC now owns 3,825 shares of the company’s stock valued at $124,000 after acquiring an additional 3,738 shares in the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).